Next Pharmaceuticals Grows through Acquisition of Sytrinol® Product and Related Intellectual Property from KGK Synergize

Salinas, California – June 5, 2013 – Next Pharmaceuticals has purchased worldwide distribution rights, along with all patents, trademarks and scientific knowledge for Sytrinol from KGK Synergize. Sytrinol is currently sold through Proprietary Nutritionals Inc., who holds distribution rights through December 31, 2013.

“Sytrinol is an exciting addition to our portfolio of patented, proven and science based products”, said Regan Miles, President of Next Pharmaceuticals. “New product acquisition is one of Next’s several key growth strategies”.

Sytrinol is a patented and proprietary formula derived from natural citrus and palm fruit extracts. It combines polymethoxylated flavones (PMFs) and delta, gamma, and alpha tocotrienols.

Clinical research has demonstrated that Sytrinol significantly aids in improving total cholesterol, LDL-cholesterol, and triglycerides up to 30%, 27%, and 34%, respectively, compared to placebo. Sytrinol has also been shown to increase HDL-cholesterol and is a powerful antioxidant. Sytrinol has been granted self-affirmed GRAS (Generally Recognized as Safe) status.

Founded in 1997, Next Pharmaceuticals provides patented, science-based natural ingredients for healthy living products in the dietary supplement, food and beverage industries. Next has successfully developed six patented and proprietary plant extracts in addition to Chromulin®, a new, safer form of the essential trace mineral chromium.

Next products help consumers cope with many of today’s most prevalent and chronic health issues, significantly expanding the choices for self-care products while providing customer brands with powerful product differentiation.

Next proprietary formulations include Relora® for stress, stress-related eating and weight management; Seditol® for improved, more restful sleep; Nexrutine® for inflammation due to over-exertion and exercise; Citri-Z® for heart health; Flavoxine® for balanced cholesterol levels, Citrofen® for joint mobility and comfort; Chromulin® for balanced blood sugar; and now Sytrinol® for cholesterol.

For more information on Next Pharmaceuticals and its ingredients, visit www.NextPharmaceuticals.com.

Ashley Beleny / Environmental Relations PR

(831) 649-2334 / ashley@enviro-rel.com

Tags: